<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00340834</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2302</org_study_id>
    <secondary_id>CFTY720D2302E1</secondary_id>
    <nct_id>NCT00340834</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase</brief_title>
  <acronym>TRANSFORMS</acronym>
  <official_title>A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod
      versus interferon β-1a to reduce the frequency of relapses in patients with
      relapsing-remitting multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study</measure>
    <time_frame>Month 0 to end of study (up to approximately 4.5 years)</time_frame>
    <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study</measure>
    <time_frame>Month 12 to end of study (up to approximately 3.5 years)</time_frame>
    <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study</measure>
    <time_frame>Baseline to end of study (up to approximately 4.5 years)</time_frame>
    <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1292</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon β-1a 30 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 1.25 mg</intervention_name>
    <description>Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.</description>
    <arm_group_label>Fingolimod 1.25 mg</arm_group_label>
    <other_name>FTY720</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5 mg</intervention_name>
    <description>Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.</description>
    <arm_group_label>Fingolimod 0.5 mg</arm_group_label>
    <other_name>FTY720</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon β-1a 30 µg</intervention_name>
    <description>Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.
Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.</description>
    <arm_group_label>Interferon β-1a 30 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis
             (MS)

          -  Patients with a relapsing-remitting disease course

          -  Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5

        Exclusion Criteria:

          -  Patients with other chronic disease of the immune system, malignancies, acute
             pulmonary disease, cardiac failure, etc

          -  Pregnant or nursing women

          -  Patients who cannot tolerate treatment with an interferon

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmacuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Neurology Associates, PC, 1809 Kress Street</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Center, 3907 Waring Road, Suite 3</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists, PC, 69 Sand Pit Road, Suite 300</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Multiple Sclerosis Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Department of Neurology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute, 2040 Whitfield Ave.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMO Corporation</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Department of Neurology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The MS Center of Vero Beach</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience and Spine Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, 1540 Sunday Drive</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology &amp; Neuroscience Associates, Inc</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Ohio Neuroscience, LLC</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <zip>44811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Neurology</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Department of Neurology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Absher Neurology, 274-A Commonwealth Drive</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Institute</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice, 3815 23rd Street</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integra Clinical Research, 4242 Medical Drive, Suite 6100</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic, P.S.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Health Associates</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurological Disorders - Aurora St. Luke's Med Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ineba</name>
      <address>
        <city>Guarda Vieja 4435, Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Rosarina de Neurorehabilitacion</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neurociencias de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C118ACK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Lenox Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J. M. Ramos Mejia</name>
      <address>
        <city>General Urquiza 609, Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FLENI</name>
      <address>
        <city>Montaneses 2325, Buenos Aires</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategic Health Evaluators</name>
      <address>
        <city>Chatswood</city>
        <state>New South Wales</state>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Department of Medicine, Level, Missenden R, Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Private Hospital</name>
      <address>
        <city>North Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Private Hospital</name>
      <address>
        <city>Suite 7E, Level 5, South Street, Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hopsital, Level 3, 16 Arnold Street</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Suite 30, Grattan St., Parkbville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4</name>
      <address>
        <city>St. Poelten</city>
        <state>Sankt Poelten</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Narvenklinik Wagner-Jauregg</name>
      <address>
        <city>Abteilung fuer Neurologie, Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik f. Neurologie Innsbruck</name>
      <address>
        <city>Anichstrasse 35, Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Nervenklinik Christian Doppler Klinik</name>
      <address>
        <city>Ignaz Harrerstr. 79 , Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangel.Krankenh./Wien-Waehring Außenstelle</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik fuer Neurologie AKH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Avenue Hippocrate 10, Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Laarbeeklaan 101, Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationaal Multiple Sclerose Centrum v.z.w</name>
      <address>
        <city>Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Rafael</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41256 900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clincas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMRPUSP</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>48000-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>RS 90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital dos Servidores do Estado</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>RJ 20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gaffree e Guinle</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>RJ 20270-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V56 2X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC MS Research, 2211 Westbrook Mall</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Medical Centre, 1 Centrepointe Drive, Suite 407</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Lemoyne Hospital</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute, 3801 University Street</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa General Hospital, 501 Smyth Rd.</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic, 48 Sidi Gaber St.</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>35, Dokki St., Apt. 4</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic, 35 Dokki St., Apt. 4</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone Cpcet, Rue Jean Moulin</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Place Amélie Raba Léon, Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Purpan</name>
      <address>
        <city>Place du Dr. Baylac, Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Poissy, 10 rue du Champ Gaillard</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoppital Pasteur, Archet II, 30 avenue de la Voie</name>
      <address>
        <city>Romaine</city>
        <zip>06602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Buchholz</city>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Erbach/Odenwald</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hennigsdorf</city>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lengerich</city>
        <zip>49525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Teupitz</city>
        <zip>15755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wermsdorf</city>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hospital of Heraklion</name>
      <address>
        <city>Voutes, Heraklion</city>
        <state>Crete</state>
        <zip>GR 71001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Errikos Dinan General Hospital, 107 Mesogion Ave.</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave.</name>
      <address>
        <city>Athens</city>
        <zip>G-156 69</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, Ethnarchou Makariou 6 &amp; Eleftheriou Venizelou 1</name>
      <address>
        <city>Athens</city>
        <zip>GR 18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Patra-RIO</name>
      <address>
        <city>Patra - RIO</city>
        <zip>GR- 26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahepa University General Hospital of Thessaloniki, 1 Stilp. Kyriakidi Str.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR 54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos es Egszstd. Centr.</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Megyei Oktató Kórház</name>
      <address>
        <city>Györ</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Csolnoky Ferenc Korhaz</name>
      <address>
        <city>Korhaz u. 1, Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Neurologiai Klinika</name>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterfy Sandor u. Hospital, Neurology</name>
      <address>
        <city>u. 8-20m, Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki korhaz</name>
      <address>
        <city>Uzsoki u. 29., Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Osp. S. Luigi</name>
      <address>
        <city>Gonzaga</city>
        <state>Orbassano</state>
        <zip>TO 10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Antonio Abate</name>
      <address>
        <city>via Pastori, 4, Gallarate</city>
        <state>VA</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Roberto Binaghi</name>
      <address>
        <city>Cagliari</city>
        <zip>CA 09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Arcispedale Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>FE 44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Vaio Fidenza</name>
      <address>
        <city>Fidenza</city>
        <zip>PR 43036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Magg. Pol. Mangiagalli e Regina Elena - Fond. IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>MI 20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>MI 20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Montichiari</name>
      <address>
        <city>Montichiari</city>
        <zip>BS 25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Neurologico C. Mondino</name>
      <address>
        <city>Pavia</city>
        <zip>PV 27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Ospedale Consorziale e Policlinico</name>
      <address>
        <city>piazza Giulio Cesare, 11 Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Ospedale S. Martino - Università degli Studi</name>
      <address>
        <city>via Antonio De Toni, 5, Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist. Neurol. Mediterraneo Neuromed</name>
      <address>
        <city>Via Atinense, 18, Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I - GM Lancisi - G.Salesi</name>
      <address>
        <city>via Conca, 71, Torrette di Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Clinicizzato Colle dell'Ara - Università G. D'Annunzio</name>
      <address>
        <city>via dei Vestini, 5 Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea - Università La Sapienza</name>
      <address>
        <city>Via di Grottarossa, 1035/1039, Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova - Università degli Studi</name>
      <address>
        <city>Via Giustiniani, 2, Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Universitaria Policlinico Tor Vergata</name>
      <address>
        <city>via Montpellier, 1, Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele - IRCCS</name>
      <address>
        <city>via Olgettina, 48/60, Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico - Università degli Studi Federico II</name>
      <address>
        <city>via Pansini, 5, Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Scienze Neurologiche Università di Catania</name>
      <address>
        <city>via Santa Sofia, 78, Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria Maggiore</name>
      <address>
        <city>via Toscana Nazionale, 17/19, Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Careggi - Università degli Studi</name>
      <address>
        <city>Viale Giovan Battista Morgagni, 85, Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center, 809 Madu 1-dong, Ilsan-gu</name>
      <address>
        <city>Kyunggi</city>
        <state>Goyang</state>
        <zip>411-764</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Univ. Med. Center,Severance Hospital, 134 Shinchon-dong, Suedaemoon-ku</name>
      <address>
        <city>Seoul</city>
        <zip>135-230</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Pook National University Hospital</name>
      <address>
        <city>Taegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando Fonseca</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Av. Dr. Bissaya Barreto, Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sto. António dos</name>
      <address>
        <city>Capuchos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de São João</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Bernardo</name>
      <address>
        <city>Rua Camilo Castelo Branco, Setubal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Carlos Haya</name>
      <address>
        <city>Avda. Carlos Haya, s/n, Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Avenida Dr. Fedriani, 3, Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitaria I, Universitaria De Bellvitge, c/o Feixa Llarga, Hospitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>C/ Dr. Martin Lagos, s/n, Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unitat de Neuroimmunologia Clinica, Hospital Vall d'Hebron</name>
      <address>
        <city>EUI-planta 2, Pg. Vall d'Hebron 119-29, Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerta de Huerro Univeristy Hospital</name>
      <address>
        <city>San Martin de Porres, 4, Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe.</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zuerich</name>
      <address>
        <city>Neurologische Klinik, Frauenklinikstrasse 26, Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel, Neurochirugishen Poliklinik</name>
      <address>
        <city>Petersgraben 4, Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Investigational Site</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W8 6RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre for Neurology and Neurosurgery</name>
      <address>
        <city>Lower Lane, Fazakerly, Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwick</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.msclinicaltrials.com</url>
    <description>Fingolimod clinical trials information website</description>
  </link>
  <link>
    <url>http://www.nejm.org</url>
    <description>Cohen JA, Barkhof F, Comi G, et al., Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. Published January 20 2010 (10.1056/NEJMoa0907839)</description>
  </link>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=6685</url>
    <description>Novartis Clinical Trial Results Database</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>January 4, 2011</results_first_submitted>
  <results_first_submitted_qc>April 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2011</results_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTY720</keyword>
  <keyword>Interferon</keyword>
  <keyword>RRMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients randomized in the Core Phase (CP) to receive 0.5 mg or 1.25 mg fingolimod received the same dose in the Extension Phase (EP). Patients randomized to receive interferon-β-1a in the CP were re-randomized to receive either 0.5 mg or 1.25 mg fingolimod in a 1:1 ratio in the EP. Upon protocol amendment, all patients received 0.5 mg fingolimod.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
        </group>
        <group group_id="P2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
        </group>
        <group group_id="P3">
          <title>Interferon β-1a 30 µg</title>
          <description>Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.</description>
        </group>
        <group group_id="P4">
          <title>Interferon β-1a/Fingolimod 1.25 mg</title>
          <description>Patients who received Interferon β-1a 30 µg in the core phase of the study were randomized to receive self-administered fingolimod 1.25 mg capsules orally once daily.</description>
        </group>
        <group group_id="P5">
          <title>Interferon β-1a/Fingolimod 0.5 mg</title>
          <description>Patients who received Interferon β-1a 30 µg in the core phase of the study were randomized to receive self-administered fingolimod 0.5 mg capsules orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Phase of Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="431"/>
                <participants group_id="P3" count="435"/>
                <participants group_id="P4" count="0">This group was formed at the beginning of the extension phase of the study.</participants>
                <participants group_id="P5" count="0">This group was formed at the beginning of the extension phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="369">On study drug: 358, Off study drug: 11</participants>
                <participants group_id="P2" count="398">On study drug: 385, Off study drug: 13</participants>
                <participants group_id="P3" count="386">On study drug: 380, Off study drug: 6</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase of Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="330">Entry into the extension phase of the study was optional.</participants>
                <participants group_id="P2" count="357">Entry into the extension phase of the study was optional.</participants>
                <participants group_id="P3" count="0">This group did not exist in the extension phase of the study.</participants>
                <participants group_id="P4" count="176">Entry into the extension phase of the study was optional.</participants>
                <participants group_id="P5" count="167">Entry into the extension phase of the study was optional.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="356"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="174"/>
                <participants group_id="P5" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="281"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="123"/>
                <participants group_id="P5" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fingolimod 1.25 mg</title>
          <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
        </group>
        <group group_id="B2">
          <title>Fingolimod 0.5 mg</title>
          <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
        </group>
        <group group_id="B3">
          <title>Interferon β-1a 30 µg</title>
          <description>Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.</description>
        </group>
        <group group_id="B4">
          <title>Interferon β-1a/Fingolimod 1.25 mg</title>
          <description>Patients who received Interferon β-1a 30 µg in the core phase of the study were randomized to receive self-administered fingolimod 1.25 mg capsules orally once daily.</description>
        </group>
        <group group_id="B5">
          <title>Interferon β-1a/Fingolimod 0.5 mg</title>
          <description>Patients who received Interferon β-1a 30 µg in the core phase of the study were randomized to receive self-administered fingolimod 0.5 mg capsules orally once daily.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="426"/>
            <count group_id="B2" value="431"/>
            <count group_id="B3" value="435"/>
            <count group_id="B4" value="174"/>
            <count group_id="B5" value="167"/>
            <count group_id="B6" value="1633"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Core phase of study. Total number of patients is 1292. Demographics are based on the randomized population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="8.39"/>
                    <measurement group_id="B2" value="36.7" spread="8.81"/>
                    <measurement group_id="B3" value="36.0" spread="8.29"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="36.2" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Extension phase of study. The number of patients in the optional extension phase was less than the overall number of baseline participants who started the study. Total number of patients is 1027. Demographics are based on the intent-to-treat population.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="8.42"/>
                    <measurement group_id="B2" value="36.5" spread="8.67"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="36.1" spread="8.11"/>
                    <measurement group_id="B5" value="36.1" spread="8.59"/>
                    <measurement group_id="B6" value="36.0" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Core phase of study. Total number of patients is 1292. Demographics are based on the randomized population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Extension phase of study. The number of patients in the optional extension phase was less than the overall number of baseline participants who started the study. Total number of patients is 1027. Demographics are based on the intent-to-treat population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Core phase of study. Total number of patients is 1292. Demographics are based on the randomized population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="295"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B5" value="NA">This group did not exist in the core phase of the study.</measurement>
                    <measurement group_id="B6" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Extension phase of study. The number of patients in the optional extension phase was less than the overall number of baseline participants who started the study. Total number of patients is 1027. Demographics are based on the intent-to-treat population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="NA">This group did not exist in the extension phase of the study.</measurement>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="58"/>
                    <measurement group_id="B6" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study</title>
        <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population (ITT): All patients who were randomized and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study</title>
          <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
          <population>Intent-to-treat population (ITT): All patients who were randomized and received at least 1 dose of study medication.</population>
          <units>Estimate relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" lower_limit="0.157" upper_limit="0.264"/>
                    <measurement group_id="O2" value="0.161" lower_limit="0.122" upper_limit="0.212"/>
                    <measurement group_id="O3" value="0.331" lower_limit="0.262" upper_limit="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study</title>
        <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study</title>
          <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
          <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
          <units>T2 lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.23"/>
                    <measurement group_id="O2" value="1.6" spread="3.16"/>
                    <measurement group_id="O3" value="2.6" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study</title>
        <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study</title>
          <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
          <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="90.92" upper_limit="95.77"/>
                    <measurement group_id="O2" value="94.1" lower_limit="91.82" upper_limit="96.33"/>
                    <measurement group_id="O3" value="92.1" lower_limit="89.45" upper_limit="94.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study</title>
        <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
        <time_frame>Month 0 to end of study (up to approximately 4.5 years)</time_frame>
        <population>Intent-to-treat population (ITT): All patients who were randomized and received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study</title>
          <description>The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was calculated using negative binomial regression adjusted by treatment, country, number of relapses in the previous 2 years, and the baseline Expanded Disability Status Scale score.</description>
          <population>Intent-to-treat population (ITT): All patients who were randomized and received at least 1 dose of study medication.</population>
          <units>Estimated relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 to Month 24, n=330, 356, 341</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" lower_limit="0.114" upper_limit="0.214"/>
                    <measurement group_id="O2" value="0.182" lower_limit="0.138" upper_limit="0.242"/>
                    <measurement group_id="O3" value="0.266" lower_limit="0.207" upper_limit="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 36, n=287, 321, 293</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" lower_limit="0.079" upper_limit="0.169"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.076" upper_limit="0.160"/>
                    <measurement group_id="O3" value="0.121" lower_limit="0.084" upper_limit="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 to Month 48, n=267, 303, 271</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable due to sparse data.</measurement>
                    <measurement group_id="O2" value="NA">Not estimable due to sparse data.</measurement>
                    <measurement group_id="O3" value="NA">Not estimable due to sparse data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 to end of study, n=36, 38, 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable due to sparse data.</measurement>
                    <measurement group_id="O2" value="NA">Not estimable due to sparse data.</measurement>
                    <measurement group_id="O3" value="NA">Not estimable due to sparse data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 0 to end of study, n=420, 429, 431</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" lower_limit="0.160" upper_limit="0.229"/>
                    <measurement group_id="O2" value="0.166" lower_limit="0.139" upper_limit="0.199"/>
                    <measurement group_id="O3" value="0.271" lower_limit="0.230" upper_limit="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study</title>
        <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
        <time_frame>Month 12 to end of study (up to approximately 3.5 years)</time_frame>
        <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study</title>
          <description>The number of new or newly enlarged T2 lesions in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.</description>
          <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
          <units>T2 lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 to Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="2.644"/>
                    <measurement group_id="O2" value="0.87" spread="1.624"/>
                    <measurement group_id="O3" value="0.97" spread="1.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 to Month 36, n=255, 289, 258</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="3.418"/>
                    <measurement group_id="O2" value="1.04" spread="4.408"/>
                    <measurement group_id="O3" value="0.72" spread="1.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 to Month 48, n=36, 34, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="1.682"/>
                    <measurement group_id="O2" value="0.59" spread="1.438"/>
                    <measurement group_id="O3" value="0.49" spread="1.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last MRI scan to end of study, n=275, 309, 290</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="7.248"/>
                    <measurement group_id="O2" value="0.86" spread="2.674"/>
                    <measurement group_id="O3" value="1.03" spread="4.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study</title>
        <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
        <time_frame>Baseline to end of study (up to approximately 4.5 years)</time_frame>
        <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 1.25 mg</title>
            <description>Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O2">
            <title>Fingolimod 0.5 mg</title>
            <description>Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.</description>
          </group>
          <group group_id="O3">
            <title>Interferon β-1a µg/Fingolimod 1.25 or 0.5 mg</title>
            <description>Patients received Interferon β-1a 30 µg in the core phase of the study (Baseline to Month 12) and were then randomized to receive self administered fingolimod capsules orally once daily, either 1.25 or 0.5 mg, for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study</title>
          <description>The EDSS is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method.</description>
          <population>Intent-to-treat population (ITT): All randomized patients who received at least 1 dose of study medication.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
                <count group_id="O2" value="429"/>
                <count group_id="O3" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free of 3-month progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.01" lower_limit="57.26" upper_limit="95.77"/>
                    <measurement group_id="O2" value="71.28" lower_limit="63.69" upper_limit="78.87"/>
                    <measurement group_id="O3" value="73.40" lower_limit="68.56" upper_limit="78.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free of 6-month progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.54" lower_limit="75.07" upper_limit="84.00"/>
                    <measurement group_id="O2" value="79.76" lower_limit="75.53" upper_limit="83.98"/>
                    <measurement group_id="O3" value="81.61" lower_limit="77.39" upper_limit="85.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>COR FTY720 1.25 mg</title>
          <description>COR FTY720 1.25 mg</description>
        </group>
        <group group_id="E2">
          <title>COR FTY720 0.5 mg</title>
          <description>COR FTY720 0.5 mg</description>
        </group>
        <group group_id="E3">
          <title>COR Interferon Beta-1a</title>
          <description>COR Interferon beta-1a</description>
        </group>
        <group group_id="E4">
          <title>EXT FTY720 1.25 mg</title>
          <description>EXT FTY720 1.25 mg</description>
        </group>
        <group group_id="E5">
          <title>EXT FTY720 0.5 mg</title>
          <description>EXT FTY720 0.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Congenital absence of cranial vault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Congenital anomaly in offspring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Tolosa-Hunt syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Complication of device insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess sweat gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Administration site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Encephalitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Complicated fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Benign mediastinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Critical illness polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Dural fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Nerve root lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Progressive relapsing multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sensorimotor disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Infertility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Spermatocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="310" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="359" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="446" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="439" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="108" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="158" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="158" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="162" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="53" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="523"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="420"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="504"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="523"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

